The legal action centers on allegations that ADMA Biologics misled shareholders between August 9, 2024, and March 25, 2026. According to the complaint, the company allegedly concealed a related-party transaction and utilized channel stuffing to artificially inflate reported revenue figures. The lawsuit further claims that the firm operated without adequate internal controls, rendering public statements regarding its business performance and operational health materially deceptive.

Investors seeking to participate or gain further clarity on their legal rights are encouraged to contact the firm directly at 310-914-5007 or via email. While those who purchased shares during the specified period are considered potential members of the class, they are not required to take immediate action to remain part of the collective suit. Individuals may also choose to retain independent counsel rather than joining the current effort led by the Frank R. Cruz office.